Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
出版年份 2021 全文链接
标题
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
作者
关键词
-
出版物
BRITISH JOURNAL OF OPHTHALMOLOGY
Volume -, Issue -, Pages bjophthalmol-2021-319637
出版商
BMJ
发表日期
2021-10-17
DOI
10.1136/bjophthalmol-2021-319637
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab—Diving Deeper for Safety and Efficacy—Reply
- (2021) Neil M. Bressler JAMA Ophthalmology
- Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of US Electronic Health Records
- (2020) Szilárd Kiss et al. OPHTHALMOLOGY
- Shift From Adalimumab Originator to Biosimilars in Denmark
- (2020) Thomas Bo Jensen et al. JAMA Internal Medicine
- Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration
- (2020) Se Joon Woo et al. JAMA Ophthalmology
- Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach
- (2019) Laurent Peyrin-Biroulet et al. Expert Review of Gastroenterology & Hepatology
- The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars
- (2019) Thomas Bo Jensen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2019) Frank G. Holz et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
- (2019) Binita Dutta et al. BIODRUGS
- Age-related macular degeneration
- (2018) Paul Mitchell et al. LANCET
- Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration
- (2018) Sophie J. Bakri et al. OPHTHALMOLOGY
- Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
- (2017) Rehan M Hussain et al. EXPERT OPINION ON EMERGING DRUGS
- The changing landscape of biosimilars in rheumatology
- (2016) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Key considerations in the preclinical development of biosimilars
- (2015) Lynne A. Bui et al. DRUG DISCOVERY TODAY
- Ranibizumab for the treatment of wet AMD: a summary of real-world studies
- (2015) V Chong EYE
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- (2014) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme
- (2013) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
- (2013) Brandon G. Busbee et al. OPHTHALMOLOGY
- Age-related macular degeneration
- (2012) Laurence S Lim et al. LANCET
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- ANATOMICAL BENEFIT FROM RANIBIZUMAB TREATMENT OF PREDOMINANTLY CLASSIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE 2-YEAR ANCHOR STUDY
- (2010) Srinivas R Sadda et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
- The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration
- (2008) Salvatore Grisanti et al. PROGRESS IN RETINAL AND EYE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now